Application of nuclear factor kappa b inhibitory protein 1 combined with a20 in the preparation of drugs for treating fatty liver and related diseases
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology that inhibits proteins and nuclear factors, and is used in gene therapy, metabolic diseases, drug combinations, etc., to achieve high safety effects
Active Publication Date: 2020-06-09
WUHAN UNIV
View PDF0 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
But there is no report about the function and application of ABIN1 of the present invention in fatty liver and related diseases
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0097] [Example 1] Effect of ABIN1 overexpression on fat accumulation in L02 cells
[0098] Construct a lentiviral expression vector that overexpresses ABIN1, transfect HEK-293T cells, package the lentivirus, infect L02 cells to construct a stable cell line that overexpresses ABIN1, and overexpress the empty vector as a control (Con), and detect stable cells by Western blot Whether the strain expresses ABIN1.
[0099] After the detection was completed, the cells were divided into 4 groups, namely: L02 empty control group, ABIN1 overexpressed L02 stable cell line control group, L02-empty experimental group, ABIN1 overexpressed L02 stable cell line experimental group. After the cells adhered to the wall and the cells were cultured to 50% healing, palmitate (PA) and oleic acid (OA) (PA 0.2mM+OA 0.4mM) were added to the two experimental groups for stimulation, and the same amount was added to the control group. After 12 hours, the cell samples of each group were collected and sta...
Embodiment 2
[0101] [Example 2] Effect of overexpression of ABIN1 on fat accumulation in mouse primary liver cells
[0102] Construct a lentiviral expression vector that overexpresses ABIN1, transfect HEK-293T cells, package the lentivirus, and infect mouse primary liver cells to construct a cell model that overexpresses ABIN1, and overexpress the empty vector as a control (Con). Blot was used to detect whether the cells in the ABIN1-infected group overexpressed ABIN1.
[0103] After the detection was completed, the cells were divided into 4 groups, namely: no-load control group, ABIN1 overexpressed cell control group, L02-no-load experimental group, and ABIN1 overexpressed cell experimental group. After the cells adhered to the wall and the cells were plated to a degree of 50% healing, palmitate (PA) and oleic acid (OA) (PA 0.2mM+OA0.4mM) were added to the two experimental groups for stimulation, and the same amount was added to the control group. After 12 hours, the cell samples of each...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses application of a nuclear factor chiB inhibition protein 1 combined with A20 to preparation of a medicine for treating fatty livers and related diseases and belongs to novel application of ABIN1 (A20binding Inhibitor of NF-KB Activation). According to the application, an L02 cell line, an ABIN1 over-expression L02 cell line, mouse primary hepatocyte cells and ABIN1 over-expression mouse primary hepatocyte cells are adopted as experiment targets, fatty liver cell models are induced through palmitic acid and oleic acid together, and oil red O dyeing results show that undercombined irritation of the palmitic acid and the oleic acid of a same concentration, the areas of red fat granules in ABIN1 over-expression L02 cells are remarkably reduced when being compared with those of L02 cells. The same oil red O dyeing result trend is also observed in mouse primary hepatocyte cells with over-expressed ABIN1, the result shows that ABIN1 over-expression has a remarkable inhibition function on lipid accumulation in palmitic acid and oleic acid induced fatty liver cells. Therefore, ABIN1 has functions of inhibiting liver lipid accumulation and protecting livers.
Description
technical field [0001] The invention belongs to the field of gene function and application, and particularly relates to a ubiquitin chain binding protein, that is, A20 binding inhibitor of NF-κB activation (ABIN1) binding to A20 in fatty liver and related diseases Function and application, and the application of ABIN1 as a target gene in the preparation of drugs for preventing, alleviating and / or treating fatty liver and related diseases. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD) is a common liver disease, which refers to chronic liver disease characterized by fatty degeneration and lipid accumulation in liver cells in addition to alcohol and other definite liver damage factors. disease. Like high blood pressure and diabetes, fatty liver has become one of the common chronic diseases of contemporary people, and it has become the second most common liver disease after viral hepatitis. The incidence rate is increasing year by year and the age is g...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more